Literature DB >> 18505848

Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii.

Tze-Peng Lim1, Kimberly R Ledesma, Kai-Tai Chang, Jing-Guo Hou, Andrea L Kwa, Michael Nikolaou, John P Quinn, Randall A Prince, Vincent H Tam.   

Abstract

Treatment of multidrug-resistant bacterial infections poses a therapeutic challenge to clinicians; combination therapy is often the only viable option for multidrug-resistant infections. A quantitative method was developed to assess the combined killing abilities of antimicrobial agents. Time-kill studies (TKS) were performed using a multidrug-resistant clinical isolate of Acinetobacter baumannii with escalating concentrations of cefepime (0 to 512 mg/liter), amikacin (0 to 256 mg/liter), and levofloxacin (0 to 64 mg/liter). The bacterial burden data in single and combined (two of the three agents with clinically achievable concentrations in serum) TKS at 24 h were mathematically modeled to provide an objective basis for comparing various antimicrobial agent combinations. Synergy and antagonism were defined as interaction indices of <1 and >1, respectively. A hollow-fiber infection model (HFIM) simulating various clinical (fluctuating concentrations over time) dosing exposures was used to selectively validate our quantitative assessment of the combined killing effect. Model fits in all single-agent TKS were satisfactory (r(2) > 0.97). An enhanced combined overall killing effect was seen in the cefepime-amikacin combination (interactive index, 0.698; 95% confidence interval [CI], 0.675 to 0.722) and the cefepime-levofloxacin combination (interactive index, 0.929; 95% CI, 0.903 to 0.956), but no significant difference in the combined overall killing effect for the levofloxacin-amikacin combination was observed (interactive index, 0.994; 95% CI, 0.982 to 1.005). These assessments were consistent with observations in HFIM validation studies. Our method could be used to objectively rank the combined killing activities of two antimicrobial agents when used together against a multidrug-resistant A. baumannii isolate. It may offer better insights into the effectiveness of various antimicrobial combinations and warrants further investigations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18505848      PMCID: PMC2493134          DOI: 10.1128/AAC.01309-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40.

Authors:  Karen Lolans; Thomas W Rice; L Silvia Munoz-Price; John P Quinn
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Mathematical formulation of additivity for antimicrobial agents.

Authors:  Adam N Boucher; Vincent H Tam
Journal:  Diagn Microbiol Infect Dis       Date:  2006-04-19       Impact factor: 2.803

Review 3.  Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa.

Authors:  Robert A Bonomo; Dora Szabo
Journal:  Clin Infect Dis       Date:  2006-09-01       Impact factor: 9.079

Review 4.  Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.

Authors:  George H Talbot; John Bradley; John E Edwards; David Gilbert; Michael Scheld; John G Bartlett
Journal:  Clin Infect Dis       Date:  2005-01-25       Impact factor: 9.079

5.  Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.

Authors:  A S Levin; A A Barone; J Penço; M V Santos; I S Marinho; E A Arruda; E I Manrique; S F Costa
Journal:  Clin Infect Dis       Date:  1999-05       Impact factor: 9.079

6.  Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro.

Authors:  G L Drusano; D Z D'Argenio; W Symonds; P A Bilello; J McDowell; B Sadler; A Bye; J A Bilello
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

7.  Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections.

Authors:  Mireia Saballs; Miquel Pujol; Fe Tubau; Carmen Peña; Abelardo Montero; M Angeles Domínguez; Francesc Gudiol; Javier Ariza
Journal:  J Antimicrob Chemother       Date:  2006-09       Impact factor: 5.790

8.  Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome.

Authors:  L-C Kuo; C-C Lai; C-H Liao; C-K Hsu; Y-L Chang; C-Y Chang; P-R Hsueh
Journal:  Clin Microbiol Infect       Date:  2007-02       Impact factor: 8.067

9.  Overview of nosocomial infections caused by gram-negative bacilli.

Authors:  Robert Gaynes; Jonathan R Edwards
Journal:  Clin Infect Dis       Date:  2005-08-16       Impact factor: 9.079

10.  Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002-2004.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2004-11-19       Impact factor: 17.586

View more
  12 in total

1.  Pharmacokinetics and Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Neutropenic Murine Pneumonia Model.

Authors:  Jian Zhou; Kimberly R Ledesma; Kai-Tai Chang; Henrietta Abodakpi; Song Gao; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

2.  Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling.

Authors:  Jürgen B Bulitta; Neang S Ly; Cornelia B Landersdorfer; Nicholin A Wanigaratne; Tony Velkov; Rajbharan Yadav; Antonio Oliver; Lisandra Martin; Beom Soo Shin; Alan Forrest; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

3.  Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii.

Authors:  Rajbharan Yadav; Cornelia B Landersdorfer; Roger L Nation; John D Boyce; Jürgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

4.  Optimizing pharmacokinetics/pharmacodynamics of β-lactam/β-lactamase inhibitor combinations against high inocula of ESBL-producing bacteria.

Authors:  Vincent H Tam; Henrietta Abodakpi; Weiqun Wang; Kimberly R Ledesma; Paul R Merlau; Katrina Chan; Rachel Altman; Truc T Tran; Michael Nikolaou; Amelia K Sofjan
Journal:  J Antimicrob Chemother       Date:  2021-01-01       Impact factor: 5.790

5.  In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria.

Authors:  Elizabeth B Hirsch; Kimberly R Ledesma; Kai-Tai Chang; Michael S Schwartz; Mary R Motyl; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2012-04-23       Impact factor: 5.191

Review 6.  In search for a synergistic combination against pandrug-resistant A. baumannii; methodological considerations.

Authors:  Stamatis Karakonstantis; Petros Ioannou; Diamantis D Kofteridis
Journal:  Infection       Date:  2022-01-04       Impact factor: 3.553

7.  Combating Carbapenem-Resistant Acinetobacter baumannii by an Optimized Imipenem-plus-Tobramycin Dosage Regimen: Prospective Validation via Hollow-Fiber Infection and Mathematical Modeling.

Authors:  Cornelia B Landersdorfer; Rajbharan Yadav; Jürgen B Bulitta; Kate E Rogers; Tae Hwan Kim; Beom Soo Shin; John D Boyce; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

8.  Time-kill effect of levofloxacin on multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: synergism with imipenem and colistin.

Authors:  A Safarika; I Galani; A Pistiki; E J Giamarellos-Bourboulis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-09-06       Impact factor: 3.267

9.  Two-drug antimicrobial chemotherapy: a mathematical model and experiments with Mycobacterium marinum.

Authors:  Peter Ankomah; Bruce R Levin
Journal:  PLoS Pathog       Date:  2012-01-12       Impact factor: 6.823

10.  The pharmaco -, population and evolutionary dynamics of multi-drug therapy: experiments with S. aureus and E. coli and computer simulations.

Authors:  Peter Ankomah; Paul J T Johnson; Bruce R Levin
Journal:  PLoS Pathog       Date:  2013-04-04       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.